This 2006 colorized scanning electron micrograph image made available by the Centers for Disease Control and Prevention shows the O157:H7 strain of the E. coli bacteria. On Wednesday, May 26, 2016, U.S. military officials reported the first U.S. human case of bacteria resistant to an antibiotic used as a last resort drug. The 49-year-old woman has recovered from an infection of E. coli resistant to colistin. But officials fear that if the resistance spreads to other bacteria, the country may soon see germs impervious to all antibiotics. (Janice Carr/CDC via AP)
© 2024 Blaze Media LLC. All rights reserved.
NEW YORK (AP) -- Officials are reporting the first U.S. human case of bacteria resistant to an antibiotic used as a last resort drug.
The 49-year-old woman has recovered. But officials fear that if the resistance spreads to other bacteria, the country may soon see germs impervious to all antibiotics.
On @NewDay, @alexgarzaMD helps us find answers about the superbug case in the US: https://t.co/pMRf1bt7Db https://t.co/FuqPJfZpkb
— New Day (@NewDay) May 27, 2016
The woman had gone to a military clinic in Pennsylvania for a urinary tract infection. Tests found she had E. coli bacteria resistant to colistin, an antibiotic of last resort. She was successfully treated for the superbug with other antibiotics.
Bacteria resistant to the colistin have been found in other countries but not in people in the U.S. The woman had not traveled recently outside the country.
Military officials reported the case Wednesday.
Want to leave a tip?
We answer to you. Help keep our content free of advertisers and big tech censorship by leaving a tip today.
Want to join the conversation?
Already a subscriber?
more stories
Sign up for the Blaze newsletter
By signing up, you agree to our Privacy Policy and Terms of Use, and agree to receive content that may sometimes include advertisements. You may opt out at any time.
© 2024 Blaze Media LLC. All rights reserved.
Get the stories that matter most delivered directly to your inbox.
By signing up, you agree to our Privacy Policy and Terms of Use, and agree to receive content that may sometimes include advertisements. You may opt out at any time.